التداخل بين دابيغاتران وفيتامين ك

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran.